TargetBeta
CLDN18
claudin 18 · also SFTPJ · Claudins
14 programs in company-led studies act on CLDN18, from 10 companies: 8 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Also acted on by the same programs
Conditions their studies are in
- Stomach Neoplasms, 7 programs
- Pancreatic Neoplasms, 6 programs
- Adenocarcinoma, 5 programs
- Adenocarcinoma Of Esophagus, 2 programs
- Biliary Tract Neoplasms, 2 programs
- Lung Neoplasms, 1 program
- Neoplasm Metastasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 · Qilu Pharmaceutical · phase 3 · NCT06942767
- Dec 2026givastomig · I-Mab Biopharma US · phase 2 · NCT04900818
- Dec 30, 2026arcotatug tavatecan · Innovent Biologics · phase 3 · NCT06238843
- Dec 30, 2026Anti-Claudin 18.2 Antibody-drug Conjugate ASP546C · Astellas Pharma · phase 2 · NCT06792435
- Dec 31, 2026zolbetuximab · Astellas Pharma · phase 4 · NCT06396091
- Jan 11, 2027terallethrin · FutureGen Biopharmaceutical (Beijing) · phase 3 · NCT06177041
- Feb 28, 2027Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 · Biokin (Shanghai) Biopharmaceutical · phase 3 · NCT07021066
- Mar 31, 2027Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360 · AstraZeneca · phase 2 · NCT06921928
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.